The telehealth has imposed itself in Europe thanks to the pandemic, mainly in its synchronous form with real -time video consultations between doctors and patients. If this model has made it possible to expand access to care, it remains constrained by the simultaneous availability of both parties, limiting its effectiveness for monitoring chronic diseases, which require support over time.
The asynchronous approach is distinguished by the delayed exchange of medical information, rather than using programmed videoconsultations, patients and practitioners communicate via micro-interactions, sharing clinical data and continuous monitoring. This relational logic responds better to the challenges of chronic pathologies, lightening the schedules of practitioners who can manage their patients without having to wedge a meeting with them.
In Europe, the model is gaining ground with the emergence of actors like Doctor.one. Founded in Warsaw in 2021, the company offers a platform allowing doctors to stay connected with their patients between two visits. Already used in obesity programs, oncology, neurology and endocrinology, it facilitated nearly 500,000 micro-interactions. The first results of a program on multiple sclerosis are encouraging: 81 % of doctors have brought in an improvement in the quality of care, with a net promoter of 93.
Doctor.ONE also convinced several pharmaceutical laboratories like Novartis, Novo Nordisk, Merck and Astrazeneca, which are based on the platform to improve the adhesion to treatment and strengthen the patient-medicine relationship beyond hospital meetings. The company recently extended its technological action field with the acquisition of Dok Dok, a Polish developer of artificial intelligence solutions for the medical sector, in order to integrate more automation and insights in care paths.
To support its expansion, Doctor.one has just raised 4 million euros in Tour Seed led by Yzr Capital, with the participation of impact ventures and existing investors. This funding must allow the company to enter the German, Spanish and British markets, to strengthen its product and AI teams.
